Canada Markets closed

Filament Health Corp. (FLHLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1783+0.0121 (+7.30%)
At close: 01:13PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1662
Open0.2989
BidN/A x N/A
AskN/A x N/A
Day's Range0.1783 - 0.2989
52 Week Range0.1662 - 0.3680
Volume1,905
Avg. Volume20,589
Market Cap29.38M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
  • CNW Group

    FILAMENT HEALTH AND CYBIN THERAPEUTICS ANNOUNCE LICENSING AGREEMENT

    Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has entered into a licensing agreement with Cybin Therapeutics ("CT"), a private therapeutic bioscience company on a mission to discover and develop psilocybin assisted therapeutic protocols to treat mild mood disorders and addictions. Under the agreement, Filament will license PEX010, its botanical psilocybin drug candida

  • CNW Group

    IIROC Trade Resumption - FH

    Trading resumes in:

  • CNW Group

    FILAMENT HEALTH RECOGNIZES THE RESTORATION OF ACCESS TO RESTRICTED DRUGS VIA THE HEALTH CANADA SPECIAL ACCESS PROGRAM

    Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) ("Filament" or the "Company"), commends the formal restoration of access to restricted drugs through the Health Canada Special Access Program (SAP). The SAP allows health care practitioners to request for patients, on an emergency basis, access to drugs that are not yet approved in Canada. Since 2013, Canadians have been unable to access restricted drugs such as psilocybin and psilocin through the SAP. Thanks to the amendment, this access ha